

In re Application of:  
Axelsson and Good  
Application No.: 10/582,946  
Filed: March 2, 2007  
Page 2

PATENT  
Atty Docket No.: INDEX1140-1

**Amendments to the Specification:**

On page 14 of the specification as filed, please amend Table 1 as follows:

Table 1. NF-kappa-B target and siRNA compound sequences (5'-3')

Target Sequence		
SEQ ID NO	Sequence	Applicant's reference no.
1	AAGGACCUAUGAGACCUUCAA	IDX 101
2	AAGAUCAAUGGUACACAGGA	IDX 105
3	AACACUGCCGAGCUAAGAUC	IDX 106
4	GAGUCAGAUCAGCUCCUAAGG	IDX 107

  

Lower Sequence		
SEQ ID NO	Sequence	Applicant's reference no.
5	UUGAAGGUCUCAUAGGUCC(D)TT *	IDX 121
6	UCCUGUGUAGCCAUGAU(D)TT	IDX 125
7	GAUCUUGAGCUCGGCAGUG(D)TT	IDX 126
8	CCUUAGGAGCUGAUCUGAC(D)TT	IDX 127

  

Upper Sequence		
SEQ ID NO	Sequence	Applicant's reference no.
9	GGACCUAUGAGACCUUCAA(D)TT*	IDX 131
10	GAUCAAUGGUACACAGGA(D)TT	IDX 135
11	CACUGCCGAGCUAAGAUC(D)TT	IDX 136
12	<u>GUCAGAUCAGCUCCUGGAA(D)TT</u> <u>GUCAGAUCAGCUCCUAAGG(D)TT</u>	IDX 137

Notes:

\* denotes that siRNA compound composed of antisense strand SEQ ID NO 5 annealed with sense strand SEQ ID NO 9 that was used in the animal proof of concept studies.

Compounds synthesized as RNA oligonucleotides with the last two nucleotides from the 3' end are DNA, denoted as (D).